No, no absolutely not!
When it comes to targeted therapies, far too many external observers do not ‘see’ beyond the pretty scenery.
There’s an old obvious yet wise fable down here in Florida, which is often applicable to early stage oncology drug development – if it looks, snaps, or waddles like an alligator, do not feed it for you will surely get bitten (badly).
In this post we take a careful look at the updated adagrasib data in colorectal cancer presented at ESMO21.
There’s a lot of nuance, subtlety and questions this trial so far has not answered, and that will need to be considered if you don’t want to run the risk of being bitten by the lurking alligators.
BSB subscribers can read more about the challenges in interpreting the adagrasib CRC data presented at this year’s ESMO congress – you can log-in or click to access our latest analysis.
This content is restricted to subscribers
